InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by EQUELS THOMAS K., Chairman & CEO. Officer active across 1 companies, notably AIM ImmunoTech Inc.. Aggregated, 17 disclosures have been recorded. Total volume traded: €51k. The latest transaction was filed on 25 April 2022 — Attribution. Regulator: SEC (Form 4). All data is free.
Declarations17 total
€46,66749,020 shares@ €0.9521.18% mcap28.9% of flow
Common Stock
SEC:0001450324-22-000002:0·
€22,10121,552 shares@ €1.025538.4% of flow
Common Stock
SEC:0001450324-21-000013·
€22,10121,552 shares@ €1.025538.4% of flow
Common Stock
SEC:0001450324-21-000012·
€22,10121,552 shares@ €1.02550.56% mcap13.7% of flow
Common Stock
SEC:0001450324-21-000012:0·
€22,10121,552 shares@ €1.02550.56% mcap13.7% of flow
Common Stock
SEC:0001450324-21-000013:0·
€13,28211,811 shares@ €1.124623.1% of flow
Common Stock
SEC:0001450324-21-000011·
€13,28211,811 shares@ €1.12460.34% mcap8.2% of flow
Common Stock
SEC:0001450324-21-000011:0·
€13,33811,627 shares@ €1.147217.0% of flow
Common Stock
SEC:0001702626-21-000002·
€13,33811,627 shares@ €1.14720.34% mcap8.5% of flow
Common Stock
SEC:0001702626-21-000002:0·
€13,34311,194 shares@ €1.191917.0% of flow
Common Stock
SEC:0001450324-21-000009·
€13,34311,194 shares@ €1.19190.34% mcap8.5% of flow
Common Stock
SEC:0001450324-21-000009:0·
€13,19410,204 shares@ €1.293116.8% of flow
Common Stock
SEC:0001450324-21-000008·
€13,19410,204 shares@ €1.29310.33% mcap8.4% of flow
Common Stock
SEC:0001450324-21-000008:0·
€13,2499,146 shares@ €1.448616.9% of flow
Common Stock
SEC:0001450324-21-000007·
€13,2499,146 shares@ €1.44860.34% mcap8.4% of flow
Common Stock
SEC:0001450324-21-000007:0·
€25,39815,625 shares@ €1.625532.3% of flow
Common Stock
SEC:0001450324-21-000002·
Ideal exit: 12 Apr 2022 (T+270)
€25,39815,625 shares@ €1.62550.64% mcap16.2% of flow
Common Stock
SEC:0001450324-21-000002:0·
Ideal exit: 12 Apr 2022 (T+270)
17 of 17 declarations
About EQUELS THOMAS K.
Thomas K. Equels is an executive at AIM ImmunoTech Inc.
